Literature DB >> 8893839

Potent immunosuppressants, 2-alkyl-2-aminopropane-1,3-diols.

T Fujita1, R Hirose, M Yoneta, S Sasaki, K Inoue, M Kiuchi, S Hirase, K Chiba, H Sakamoto, M Arita.   

Abstract

Several immunosuppressants, ISP-I [(2S,3R,4R)-(E)-2-amino-3,4-dihydroxy-2-(hydroxymethyl)-14-oxoeicos++ +-6-enoic acid, myriocin = thermozymocidin] and mycestericins A-G, were isolated from culture broths of Isaria sinclairii and Mycelia sterilia, respectively. In order to investigate structure-activity relationships, extensive modifications of ISP-I were conducted, and it was established that the fundamental structure possessing the immunosuppressive activity is a symmetrical 2-alkyl-2-aminopropane-1,3-diol. The tetradecyl, pentadecyl, and hexadecyl derivatives prolonged rat skin allograft survival in the combination of LEW donor and F344 recipient and were more effective than cyclosporin A. Among them, 2-amino-2-tetradecylpropane-1,3-diol hydrochloride, ISP-I-55, showed the lowest toxicity. ISP-I-55 is a promising lead compound for the development of effective immunosuppressants for organ transplantations and for the treatment of autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8893839     DOI: 10.1021/jm960391l

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  24 in total

1.  Role of extracelluar regulated protein kinases in FTY720-induced apoptosis of leukemia cell lines HL-60 and U937.

Authors:  Dengju Li; Yaozhen Zhang; Xiangrong Hu; Wenjing Cao; Wei Huang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2004

Review 2.  Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics.

Authors:  Alfred H Merrill
Journal:  Chem Rev       Date:  2011-09-26       Impact factor: 60.622

3.  Fingolimod: Lessons Learned and New Opportunities for Treating Multiple Sclerosis and Other Disorders.

Authors:  Jerold Chun; Yasuyuki Kihara; Deepa Jonnalagadda; Victoria A Blaho
Journal:  Annu Rev Pharmacol Toxicol       Date:  2019-01-06       Impact factor: 13.820

4.  FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats, III. Increase in frequency of CD62L-positive T cells in Peyer's patches by FTY720-induced lymphocyte homing.

Authors:  Y Yanagawa; Y Masubuchi; K Chiba
Journal:  Immunology       Date:  1998-12       Impact factor: 7.397

Review 5.  Discovery of fingolimod based on the chemical modification of a natural product from the fungus, Isaria sinclairii.

Authors:  Kenji Chiba
Journal:  J Antibiot (Tokyo)       Date:  2020-07-17       Impact factor: 2.649

6.  Short-term KRP203 and posttransplant cyclophosphamide for graft-versus-host disease prophylaxis.

Authors:  Emi Yokoyama; Daigo Hashimoto; Eiko Hayase; Takahide Ara; Reiki Ogasawara; Shuichiro Takahashi; Hiroyuki Ohigashi; Takahiro Tateno; Yuta Hasegawa; Xuanzhong Chen; Takanori Teshima
Journal:  Bone Marrow Transplant       Date:  2019-11-04       Impact factor: 5.483

7.  T cell selective apoptosis by a novel immunosuppressant, FTY720, is closely regulated with Bcl-2.

Authors:  Yukitoshi Nagahara; Masahiko Ikekita; Takahisa Shinomiya
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

Review 8.  A Chemoattractant-Guided Walk Through Lymphopoiesis: From Hematopoietic Stem Cells to Mature B Lymphocytes.

Authors:  Vivian Y Lim; Sandra Zehentmeier; Chris Fistonich; João P Pereira
Journal:  Adv Immunol       Date:  2017-03-18       Impact factor: 3.543

9.  VEGF and bFGF increase survival of xenografted human ovarian tissue in an experimental rabbit model.

Authors:  Lin Wang; Ying-fen Ying; Yin-luan Ouyang; Jing-fen Wang; Jian Xu
Journal:  J Assist Reprod Genet       Date:  2013-09-06       Impact factor: 3.412

10.  FTY720 story. Its discovery and the following accelerated development of sphingosine 1-phosphate receptor agonists as immunomodulators based on reverse pharmacology.

Authors:  Kunitomo Adachi; Kenji Chiba
Journal:  Perspect Medicin Chem       Date:  2007-09-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.